News Releases

Email Alerts

Sep 5, 2017

Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)

Study met primary endpoint of culture conversion (p < 0.0001)

BRIDGEWATER, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Sep 5, 2017

Insmed Announces Proposed Public Offering of Common Stock

BRIDGEWATER, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $250 million of shares of its...
Aug 3, 2017

Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update

On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month

BRIDGEWATER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
Jul 27, 2017

Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017

BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
Jul 12, 2017

Insmed to Host Analyst and Investor Day on July 19, 2017

BRIDGEWATER, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced...
Jun 13, 2017

Insmed to Present at the JMP Securities Life Sciences Conference

BRIDGEWATER, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced...
Jun 8, 2017

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., June 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today...
May 15, 2017

Insmed Announces Key Additions to its Executive Management Team

Paolo Tombesi named as Chief Financial Officer

BRIDGEWATER, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
May 3, 2017

Insmed Reports First Quarter 2017 Financial Results and Provides Business Update

Advancing Toward Top-Line Results from CONVERT Study in 2H 2017

BRIDGEWATER, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported...
Apr 27, 2017

Insmed to Present at the Deutsche Bank 42nd Annual Health Care Conference

BRIDGEWATER, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced...

Show per page